Last updated on August 2019

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer


Brief description of study

This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. The study duration is 24 months.

Clinical Study Identifier: NCT03022825

Find a site near you

Start Over

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Virginia Urology

Richmond, VA United States
  Connect »

Manhattan Medical Research

New York, NY United States
  Connect »

Skyline Urology

Torrance, CA United States
  Connect »

UNC Chapel Hill

Chapel Hill, NC United States
  Connect »

Seton Medical Center

Daly City, CA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Toledo Clinic

Toledo, OH United States
  Connect »

Clinical Research Solutions

Middleburg Heights, OH United States
  Connect »

University of Rochester

Rochester, NY United States
  Connect »

West Coast Urology

Inglewood, CA United States
  Connect »

UCLA Department of Urology

Los Angeles, CA United States
  Connect »

Skyline Urology

Sherman Oaks, CA United States
  Connect »

Urology Associates, PC

Englewood, CO United States
  Connect »

Moffit Cancer Center

Tampa, FL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »